
Quarterly report 2025-Q3
added 11-06-2025
Apyx Medical Corporation Cash Flow 2011-2025 | APYX
Annual Cash Flow Apyx Medical Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-5.25 M | -20.3 M | -10.4 M | -16.1 M | -18.5 M | -20.9 M | -3.7 M | -2.84 M | -5.79 M | -417 K | -2.54 M | 165 K | 1.9 M |
Depreciation & Amortization |
692 K | 890 K | 903 K | 887 K | 754 K | 669 K | 696 K | 734 K | 812 K | 876 K | 827 K | 742 K | 753 K |
Accounts Payables |
2.71 M | 2.67 M | 2.63 M | 1.51 M | 2.44 M | 1.42 M | 1.58 M | 1.61 M | 1.21 M | 1.55 M | 1.06 M | 803 K | 1.08 M |
Accounts Receivables |
14 M | 10.6 M | 13 M | 8.4 M | 7.99 M | 3.72 M | 4.86 M | 4.73 M | 2.92 M | 1.99 M | 1.99 M | 2.87 M | 2.22 M |
Total Inventories |
9.92 M | 11.8 M | 6.78 M | 4.05 M | 5.07 M | 3.15 M | 4.27 M | 6.16 M | 5.96 M | 5.73 M | 8.42 M | 7.54 M | 8.18 M |
All numbers in USD currency
Quarterly Cash Flow Apyx Medical Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -702 K | - | - | - | -6.34 M | - | - | - | -1.88 M | - | -15.8 M | -10.4 M | -4.52 M | - | -10.7 M | -7.06 M | -2.05 M | - | -15 M | -12.4 M | -7.41 M | - | -15.2 M | -10.7 M | -5.09 M | - | -2.84 M | -1.68 M | -1.11 M | - | -4.44 M | -3.89 M | -2.82 M | - | -2.29 M | -2.38 M | -2.27 M | - | -4.76 M | -4.12 M | -1.79 M | - | -615 K | -1.31 M | -1.05 M | - | -1.19 M | -1.27 M | -253 K | - | 154 K | 454 K | -486 K | - | 2.14 M | 2.22 M | 737 K |
Depreciation & Amortization |
- | - | 138 K | - | - | - | 157 K | - | - | - | 203 K | - | 688 K | 472 K | 225 K | - | 674 K | 440 K | 227 K | - | 662 K | 439 K | 214 K | - | 510 K | 316 K | 194 K | - | 58 K | 172 K | 199 K | - | 171 K | 178 K | 178 K | - | 201 K | 173 K | 182 K | - | 631 K | 421 K | 217 K | - | 656 K | 453 K | 232 K | - | 620 K | 416 K | 212 K | - | 640 K | 440 K | 224 K | - | 677 K | 453 K | 229 K |
Accounts Payables |
3.22 M | 2.89 M | 2.3 M | 2.62 M | 1.91 M | 2.35 M | - | 2.71 M | 2.05 M | - | 1.9 M | 2.67 M | 2.07 M | 2.59 M | 2.56 M | 2.63 M | 3.04 M | 2.8 M | 2.28 M | 1.51 M | 1.51 M | 1.51 M | 1.51 M | 2.44 M | 2.44 M | 2.44 M | 2.44 M | 1.42 M | 1.42 M | 1.42 M | 1.42 M | 1.58 M | 1.58 M | 1.58 M | 1.58 M | 1.61 M | 1.61 M | 1.61 M | 1.61 M | 1.21 M | 1.21 M | 1.21 M | 1.21 M | 1.55 M | 1.55 M | 1.55 M | 1.55 M | 1.06 M | 1.06 M | 1.06 M | 1.06 M | 803 K | 803 K | 803 K | 803 K | 1.08 M | 1.08 M | 1.08 M | 1.08 M |
Accounts Receivables |
13 M | 11.2 M | 11.6 M | 15.5 M | 13 M | 12.7 M | - | 14 M | 12.6 M | - | 9.97 M | 10.6 M | 9.09 M | 10.3 M | 12.4 M | 13 M | 11.4 M | 8.98 M | 7.68 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 7.99 M | 7.99 M | 7.99 M | 7.99 M | 5.08 M | 5.02 M | 5.02 M | 5.02 M | 4.86 M | 4.86 M | 4.86 M | 4.86 M | 4.73 M | 4.73 M | 4.73 M | 4.73 M | 2.92 M | 2.92 M | 2.92 M | 2.92 M | 1.99 M | 1.99 M | 1.99 M | 1.99 M | 1.99 M | 1.99 M | 1.99 M | 1.99 M | 2.87 M | 2.87 M | 2.87 M | 2.87 M | 2.22 M | 2.22 M | 2.22 M | 2.22 M |
Total Inventories |
9.14 M | 8.19 M | 7.68 M | 7.56 M | 9 M | 9.32 M | - | 9.92 M | 11.3 M | - | 10.9 M | 11.8 M | 12 M | 9.68 M | 7.02 M | 6.78 M | 6.04 M | 5.27 M | 4.46 M | 4.05 M | 4.05 M | 4.05 M | 4.05 M | 5.07 M | 5.07 M | 5.07 M | 5.07 M | 5.3 M | 5.21 M | 5.21 M | 5.21 M | 4.27 M | 4.27 M | 6.53 M | 6.53 M | 6.16 M | 6.16 M | 6.16 M | 6.16 M | 5.96 M | 5.96 M | 5.96 M | 5.96 M | 5.73 M | 5.73 M | 5.73 M | 5.73 M | 8.42 M | 8.42 M | 8.42 M | 8.42 M | 7.54 M | 7.54 M | 7.54 M | 7.98 M | 8.18 M | 8.18 M | 8.18 M | 8.18 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Apyx Medical Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
Abiomed
ABMD
|
- | - | $ 17.2 B | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
Bio-Rad Laboratories
BIO
|
$ 307.92 | -1.93 % | $ 8.69 B | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Bruker Corporation
BRKR
|
$ 45.13 | -2.67 % | $ 6.72 K | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Abbott Laboratories
ABT
|
$ 125.1 | 1.48 % | $ 218 B | ||
|
Boston Scientific Corporation
BSX
|
$ 92.34 | 0.64 % | $ 136 B | ||
|
EDAP TMS S.A.
EDAP
|
$ 2.56 | 8.94 % | $ 95.5 M | ||
|
Invacare Corporation
IVC
|
- | - | $ 24.7 M | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
$ 0.92 | -4.72 % | $ 14.8 M | ||
|
IRadimed Corporation
IRMD
|
$ 96.35 | -1.06 % | $ 1.22 B | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 17.7 | -3.46 % | $ 408 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
$ 62.79 | -1.82 % | $ 3.41 B | ||
|
Pulmonx Corporation
LUNG
|
$ 2.53 | 0.86 % | $ 99 M | ||
|
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | ||
|
InMode Ltd.
INMD
|
$ 14.56 | 0.76 % | $ 1.15 B | ||
|
Cognyte Software Ltd.
CGNT
|
$ 9.88 | 0.05 % | $ 709 M | ||
|
Myomo
MYO
|
$ 1.06 | -1.85 % | $ 7.47 M | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 13.41 | -4.56 % | $ 1.03 B | ||
|
NuVasive
NUVA
|
- | - | $ 2.07 B | ||
|
Align Technology
ALGN
|
$ 165.15 | 0.78 % | $ 12.4 B | ||
|
Accuray Incorporated
ARAY
|
$ 1.07 | -3.18 % | $ 110 M | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
$ 12.81 | -1.23 % | $ 346 M | ||
|
Orthofix Medical
OFIX
|
$ 15.51 | -1.27 % | $ 591 M | ||
|
FONAR Corporation
FONR
|
$ 14.86 | -0.03 % | $ 97.4 M | ||
|
AxoGen
AXGN
|
$ 30.33 | 1.15 % | $ 1.34 B | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
GBS
GBS
|
- | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
$ 40.78 | 2.33 % | $ 1.26 B | ||
|
LENSAR
LNSR
|
$ 11.48 | -0.17 % | $ 132 M |